Radio-Chemotherapy in Pre-Operative Rectal Adenocarcinoma at Dalal Jamm Hospital, Senegal

M. Bâ, F. Sarr, A. Diallo, M. Mane, Pape Massamba Diéne, P. Gaye
{"title":"Radio-Chemotherapy in Pre-Operative Rectal Adenocarcinoma at Dalal Jamm Hospital, Senegal","authors":"M. Bâ, F. Sarr, A. Diallo, M. Mane, Pape Massamba Diéne, P. Gaye","doi":"10.4236/JCT.2021.124021","DOIUrl":null,"url":null,"abstract":"Background: Radiation therapy is an essential treatment for rectal cancer. In 2018, Senegal \nexperienced a transition from two-dimensional to three-dimensional radiotherapy \n(RC3D). We are evaluating for the first time the impact of this RC3D in the \ntreatment of rectal cancer in Senegal. Objective: To describe the epidemiological, clinical and diagnostic \nprofile of rectum cancer in Senegal, to list the different radiotherapy \ntechniques used, to evaluate the response as well \nas the outcome of patients. Method: We conducted a retrospective descriptive study on preoperative \nradio-chemotherapy of rectal adenocarcinoma at the Dalal Jamm University \nHospital in Dakar from July 2018 to June 2020. Results: The 42 patients \nincluded, including 18 men and 24 women (Sex Ratio: 0.75), had an average age \nof 55.9 years. We found a family history of CRC (Colorectal cancer) in 7 cases \nand smoking in 5 cases. The clinical signs were dominated by rectal bleeding, \nnoted in 92.8% of cases, with or without pain, and changes in transit in 57.1% \nand 50% respectively. The tumor was perceptible on digital rectal examination \n(DRE) in 76.1%. All patients had undergone endoscopy, which revealed a budding \naspect in 69% of cases. The preferred location was the lower rectum (59.5%). \nThe predominant histological type was liberkhunian adenocarcinoma (85.7%). T3 \nand T4 tumors accounted for 30.9% and 21.4% of cases respectively and stage III \nwas predominant, 69%. The aim of radiotherapy was curative in 33 patients and \npalliative in 9 patients. Curative radiotherapy was preoperative in 29 patients \nand adjuvant in 2 patients. RC3D was the technique used in all our patients and \nthe total dose of 50.4 Gy in 28 sessions of 5 days per week was the most used \n(69%). The incidents noted during radiotherapy were 12 cases of \nradiodermatitis, 15 cases of diarrhea, and no severe toxicity was noted. \nThirty-one patients underwent surgery, 16 with anterior resection of the rectum \nand 3 with total proctectomy; the sphincter preservation rate was 61.2%. The \nsurgical resection was carcinological (R0) in 26 patients and microscopically \nincomplete (R1) in 5 patients. Post-operative evaluation of the pathological \nspecimen showed a complete histological response in 21% of cases. The evolution \nwas marked by a progressive disease in 4 cases, local recurrence in 3 cases, \nmetastatic recurrence in 4 cases, death in 8 cases and remission in 23 cases. The average follow-up of our \npatients was 17.3 months. Conclusion: Rectal cancer is diagnosed \nlate in Senegal; surgery remains the cornerstone of treatment. Radiotherapy \nincreases the resectability and local control.","PeriodicalId":66197,"journal":{"name":"癌症治疗(英文)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症治疗(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/JCT.2021.124021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Radiation therapy is an essential treatment for rectal cancer. In 2018, Senegal experienced a transition from two-dimensional to three-dimensional radiotherapy (RC3D). We are evaluating for the first time the impact of this RC3D in the treatment of rectal cancer in Senegal. Objective: To describe the epidemiological, clinical and diagnostic profile of rectum cancer in Senegal, to list the different radiotherapy techniques used, to evaluate the response as well as the outcome of patients. Method: We conducted a retrospective descriptive study on preoperative radio-chemotherapy of rectal adenocarcinoma at the Dalal Jamm University Hospital in Dakar from July 2018 to June 2020. Results: The 42 patients included, including 18 men and 24 women (Sex Ratio: 0.75), had an average age of 55.9 years. We found a family history of CRC (Colorectal cancer) in 7 cases and smoking in 5 cases. The clinical signs were dominated by rectal bleeding, noted in 92.8% of cases, with or without pain, and changes in transit in 57.1% and 50% respectively. The tumor was perceptible on digital rectal examination (DRE) in 76.1%. All patients had undergone endoscopy, which revealed a budding aspect in 69% of cases. The preferred location was the lower rectum (59.5%). The predominant histological type was liberkhunian adenocarcinoma (85.7%). T3 and T4 tumors accounted for 30.9% and 21.4% of cases respectively and stage III was predominant, 69%. The aim of radiotherapy was curative in 33 patients and palliative in 9 patients. Curative radiotherapy was preoperative in 29 patients and adjuvant in 2 patients. RC3D was the technique used in all our patients and the total dose of 50.4 Gy in 28 sessions of 5 days per week was the most used (69%). The incidents noted during radiotherapy were 12 cases of radiodermatitis, 15 cases of diarrhea, and no severe toxicity was noted. Thirty-one patients underwent surgery, 16 with anterior resection of the rectum and 3 with total proctectomy; the sphincter preservation rate was 61.2%. The surgical resection was carcinological (R0) in 26 patients and microscopically incomplete (R1) in 5 patients. Post-operative evaluation of the pathological specimen showed a complete histological response in 21% of cases. The evolution was marked by a progressive disease in 4 cases, local recurrence in 3 cases, metastatic recurrence in 4 cases, death in 8 cases and remission in 23 cases. The average follow-up of our patients was 17.3 months. Conclusion: Rectal cancer is diagnosed late in Senegal; surgery remains the cornerstone of treatment. Radiotherapy increases the resectability and local control.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
塞内加尔Dalal Jamm医院直肠腺癌术前放化疗
背景:放射治疗是直肠癌的基本治疗方法。2018年,塞内加尔经历了从二维到三维放射治疗(RC3D)的过渡。我们正在首次评估RC3D在塞内加尔直肠癌治疗中的影响。目的:描述塞内加尔直肠癌的流行病学,临床和诊断概况,列出使用的不同放疗技术,评估患者的反应和结果。方法:对达喀尔Dalal Jamm大学医院2018年7月至2020年6月直肠腺癌术前放化疗进行回顾性描述性研究。结果:42例患者,男18例,女24例,性别比0.75,平均年龄55.9岁。有结直肠癌家族史者7例,吸烟者5例。临床症状以直肠出血为主,占92.8%,伴或不伴疼痛,转运改变分别占57.1%和50%。直肠指检(DRE)可检出肿瘤的占76.1%。所有患者都进行了内窥镜检查,69%的病例显示出萌芽。首选部位为下直肠(59.5%)。以liberkhunia腺癌为主(85.7%)。T3和T4肿瘤分别占30.9%和21.4%,以III期肿瘤为主,占69%。放疗的目的是治愈33例,缓解9例。术前放疗29例,辅助放疗2例。RC3D是我们所有患者使用的技术,每周5天,共28次,总剂量为50.4 Gy,使用最多(69%)。放射治疗期间发生放射性皮炎12例,腹泻15例,未见严重毒性。31例患者行手术治疗,其中16例行直肠前切除术,3例行全直肠切除术;括约肌保存率为61.2%。手术切除26例为癌性(R0), 5例为镜下不完全(R1)。术后病理标本的评估显示21%的病例有完全的组织学反应。4例病情进展,3例局部复发,4例转移性复发,8例死亡,23例缓解。患者平均随访17.3个月。结论:塞内加尔直肠癌诊断较晚;手术仍然是治疗的基石。放射治疗增加了可切除性和局部控制性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
1185
期刊最新文献
Comprehensive Analysis of Cancer Incidence and Mortality Trends in Costa Rica: Implications for Public Health. Bat 26 Microsatellite Instability in Oral Cavity Cancers in Senegal Recent Advances in Metabolomics and Therapeutics for Cancer Cachexia Advanced Cutaneous Scalp Eccrine Adenocarcinoma, Diagnosis and Treatment Challenges: A Case Report The Psychological Experience of the Nursing Staff of the Medical Oncology Department in Cameroon: Case of the Yaoundé General Hospital
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1